There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Irhythm Technologies (IRTC – Research Report) and Arvinas Holding Company (ARVN – Research Report) with bullish sentiments.
Irhythm Technologies (IRTC)
Morgan Stanley analyst Cecilia Furlong maintained a Buy rating on Irhythm Technologies today and set a price target of $172.00. The company’s shares closed last Thursday at $127.80.
According to TipRanks.com, Furlong is a 4-star analyst with an average return of
Irhythm Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $171.50, representing a 29.5% upside. In a report issued on September 12, J.P. Morgan also maintained a Buy rating on the stock with a $185.00 price target.
See today’s best-performing stocks on TipRanks >>
Arvinas Holding Company (ARVN)
BMO Capital analyst Etzer Darout maintained a Buy rating on Arvinas Holding Company today and set a price target of $95.00. The company’s shares closed last Thursday at $42.65, close to its 52-week low of $34.90.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arvinas Holding Company with a $87.82 average price target, a 100.6% upside from current levels. In a report issued on September 9, Barclays also initiated coverage with a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IRTC:
- Trillium Gold Closes Oversubscribed C$4.1 Million Brokered Private Placement
- BMO Capital Keeps Their Buy Rating on Glatfelter (GLT)
- Altus Power (AMPS) Receives a Hold from Morgan Stanley
- Morgan Stanley Remains a Hold on Fluence Energy (FLNC)
- Morgan Stanley Reaffirms Their Hold Rating on TPI Composites (TPIC)
